WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MLYS earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$71.9M
Current Profit Margin
0%

MLYS Return on Equity

Current Company
-26.5%
Current Industry
-63.5%
Current Market
188%
MLYS's Return on Equity (-26.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MLYS announces earnings.

MLYS Return on Assets

Current Company
-25.5%
Current Industry
2.9%
MLYS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MLYS Return on Capital Employed

Current Company
-29.81%
Current Industry
19.5%
MLYS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MLYS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MLYS$0.00-$71.90M-$71.90MN/AN/A
PRME$0.00-$180.97M-$198.13M-100.00%N/A
CVAC$45.62M-$294.67M-$321.59M-24.38%N/A
OLMA$0.00-$94.98M-$96.66MN/AN/A
GHRS$0.00-$34.55M-$35.59MN/AN/A
View Top Biotech Stocks

MLYS earnings dates

Next earnings date
May 13, 2024

Mineralys Therapeutics Earnings & Revenue FAQ

What were MLYS's earnings last quarter?

On Invalid Date, Mineralys Therapeutics (NASDAQ: MLYS) reported Q4 2023 earnings per share (EPS) of -$0.63, up 64% year over year. Total Mineralys Therapeutics earnings for the quarter were -$24.39 million. In the same quarter last year, Mineralys Therapeutics's earnings per share (EPS) was -$1.75.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.

What was MLYS's earnings growth in the past year?

As of Q2 2024, Mineralys Therapeutics's earnings has grown year over year. Mineralys Therapeutics's earnings in the past year totalled -$71.90 million.

What is MLYS's earnings date?

Mineralys Therapeutics's earnings date is Invalid Date. Add MLYS to your watchlist to be reminded of MLYS's next earnings announcement.

What was MLYS's revenue last quarter?

On Invalid Date, Mineralys Therapeutics (NASDAQ: MLYS) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Mineralys Therapeutics's revenue was $0.00.

What was MLYS's revenue growth in the past year?

As of Q2 2024, Mineralys Therapeutics's revenue has grown null year over year. Mineralys Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.